A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: The women's health in the Lund area (WHILA) study (Sweden)

Cancer Causes and Control

Volumn 14, Issue 7, 2003, Pages 673-680

  Jernström, Helena ^a   Bendahl, Pär Ola ^a   Lidfeldt, Jonas ^a   Nerbrand, Christina ^a   Agardh, Carl David ^a   Samsioe, Göran ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast neoplasm; Cohort study; Estrogen; Hormone replacement therapy; Progestin

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HAZARD ASSESSMENT; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; SWEDEN;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; RISK FACTORS; SWEDEN;

EID: 0141639805     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025635720208     Document Type: Article

References (31)

1. Arrenbrecht S, Boermans AJ (2002) Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo- controlled trial. Osteoporos Int 13(2): 176-183.
2. Hulley S, Grady D, Bush T, et al. (1998) Randomized trial of estrogen plus progesin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280(7): 605-613.
3. Mosca L, Collins P, Herrington DM, et al. (2001) Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 104(4): 499-503.
4. Hemminki E, McPherson K (1997) Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. Br Med J 315(7101): 149-153.
5. Rossouw JE, Anderson GL, Prentice RL, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288(3): 321-333.
6. Olsson H, Bladström A, Ingvar C, Möller TR (2001) A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 85(5): 674-677.
7. Collaborative group on hormonal factors in breast cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047-1059.
8. Jernström H, Frenander J, Ferno M, Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80(9): 1453-1458.
9. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen-and oestrogen- progestin-replacement therapy. Int J Cancer 81(3): 339-344.
10. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283(4): 485-491.
11. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, et al. (2002) Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 100(6): 1148-1158.
12. Li C, Wilawan K, Samsioe G, Lidfeldt J, Agardh CD, Nerbrand C (2002) Health profile of middle-aged women: The Women's Health in the Lurid Area (WHILA) study. Hum Reprod 17(5): 1379-1385.
13. Lidfeldt J, Holmdahl L, Samsioe G, et al. (2002) The influence of hormonal status and features of the metabolic syndrome on bone density: a population-based study of Swedish women aged 50 to 59 years. The women's health in the Lund area study. Metabolism 51(2): 267-270.
14. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies. Br J Cancer 69: 979-985.
15. Pike MC, Ross RK, Spicer DV (1998) Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 147(8): 718-721.
16. Pike MC, Ross RK (2000) Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 65(10-11): 659-664.
17. Wells M, Sturdee DW, Barlow DH, et al. (2002) Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. Br Med J 325(7358): 239.
18. Olsson H, Jernström H, Alm A, et al. (1996) Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use and reproductive factors. Breast Cancer Res Treat 40: 187-196.
19. Russo J, Tay L, Russo I (1982) Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2(1): 5-73.
20. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50(23): 7415-7421.
21. Söderqvist G, Leifland K, Olsson H, Järbrink K (2002). Lilla bröstboken-nytt om hormoneffekter på bröstvävnad. Västra Frölunda: Organon AB.
22. Conner P, Skoog L, Soderqvist G (200t) Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology. Climacteric 4(1): 7-12.
23. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4): 328-332.
24. Wolfe JN (1976) Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37(5): 2486-2492.
25. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(12): 1133-1144.
26. Lundström E, Wilczek B, von Palffy Z, Söderqvist G, von Schoultz B (1999) Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 181(2): 348-352.
27. Colacurci N, Fornaro F, De Franciscis P, Mele D, Palermo M, del Vecchio W (2001) Effects of short time suspension of hormone replacement therapy on mammographic density. Fertil Steril 76: 451-455.
28. Kavanagh AM, Mitchell H, Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355(9200): 270-274.
29. Key T, Pike M (1988) The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24(1): 29-43.
30. Hankinson SE, Willett WC, Manson JE, et al. (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87: 1297-1302.
31. Ensrud KE, Lipschutz RC, Cauley JA, et al. (1997) Body size and hip fracture risk in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Am J Med 103(4): 274-280.